Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 August 2025 | Story Martinette Brits | Photo Stephen Collett
Prof Yonas Bahta
Prof Yonas Bahta, Professor in the Department of Agricultural Economics at the University of the Free State, delivered his inaugural lecture on the future of agricultural trade and food security, titled Can We Own the Future? The Ever-Changing Dynamics of Agricultural Trade and Food Security Amid Intensifying Agricultural Drought.

With the world hurtling towards a population of 9,7 billion by 2050 – and Africa set to make up more than a quarter of that – the question of whether we can ‘own the future’ has never been more urgent. In his inaugural lecture at the University of the Free State (UFS), Prof Yonas Bahta from the Department of Agricultural Economics warned that climate change, trade tensions, and deepening food insecurity are converging to create unprecedented risks for farmers, economies, and communities.

“We find ourselves at a pivotal moment in human history, characterised by the intersection of climate change, particularly agricultural drought, resource scarcity, geopolitical instability, and the current trade reciprocal tariff, all of which pose significant threats to the foundational structures of global food systems,” he said.

 

From vulnerability to agency

Prof Bahta highlighted the stark reality that the world population is projected to reach 9,7 billion by 2050, with Africa constituting 2,5 billion. “Despite this growth, the agricultural sector predominantly operates at a subsistence level, with diminishing resources available to farming communities, especially smallholder farmers who rely on agriculture as their primary source of employment and sustenance.”

In South Africa, climate change – particularly agricultural drought – is affecting both commercial and smallholder farmers, with cascading effects on food security, employment, and livelihoods. Coupled with disease outbreaks, these factors lead to reduced crop yields, supply shocks, and trade imbalances that ripple through the economy.

Food insecurity remains a critical concern, with approximately 15 million South African households experiencing moderate to severe food insecurity – a figure even higher (25,5%) among households engaged in agricultural activities. Prof Bahta emphasised that these challenges are compounded by “institutional barriers such as the current trade reciprocal tariff by the USA, limited access to credit, crop and livestock insurance, inadequate road infrastructure, and electricity shortages”.

Despite these challenges, Prof Bahta sees clear opportunities. He pointed to Africa, including South Africa’s extensive arable land; research and innovation have highlighted the benefits of integrating traditional techniques with modern approaches such as climate-smart agriculture and its membership of BRICS and other trading partners as levers for resilience and growth. “Securing the future is not about mere assertion but about the stewardship of markets, data, and people,” he said. By aligning trade policy, drought preparedness, and social protection within robust institutions, “the country can transition from vulnerability to agency, from passively observing the future to actively shaping it. In doing so, we may indeed assert with integrity that ‘We own the future’.”

 

About Prof Yonas Bahta

Prof Yonas Bahta is a Professor and NRF-rated researcher in the Department of Agricultural Economics at the University of the Free State. He joined the UFS as a researcher in 2014 and has supervised more than 42 postgraduate students (both MSc and PhD), of whom 29 have completed their studies (10 PhD and 19 MSc).

He holds a PhD (2007) and MSc (2004, with distinction) in Agricultural Economics from the UFS, and a BSc (1994) in Agricultural Economics from Haramaya University, Ethiopia. Prof Bahta serves on the editorial boards of several journals, acts as a reviewer and guest editor, and is a member of several national and international professional bodies.

His work has been recognised with an award from the African Growth and Development Policy Modelling Consortium (AGRODEP), and in 2024 he was rated among the top 2% of researchers globally by Elsevier.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept